Palvella Therapeutics (PVLA) FCF Margin (2014 - 2024)
Palvella Therapeutics' (PVLA) quarterly FCF Margin came in at 2079.25% in Q1 2024, down 152979.0% year-on-year from N/an in Q2 2023, and down 184.55% on a QoQ basis from 730.71% in Q4 2023.
Palvella Therapeutics (PVLA) FCF Margin (2014 - 2024) Analysis & Trends
Palvella Therapeutics (PVLA) has 11 years of FCF Margin data on file, last reported at 2079.25% in Q1 2024.
- On a quarterly basis, FCF Margin fell 152979.0% year-over-year to 2079.25% in Q1 2024; TTM through Sep 2024 was 546.52%, a 43081.0% decrease from a year earlier, with the FY2023 full-year figure at 35.84%, up 1404568.0% from the prior year.
- FCF Margin for Q1 2024 stood at 2079.25%, down from 730.71% in the prior quarter.
- Over the last five years, FCF Margin for PVLA reached as high as 3983.49% in Q2 2021 and fell as low as 10177.37% in Q4 2022.
- Historically, FCF Margin has averaged 1213.68% across 5 years, with a median of 209.61% in 2022.
- Across the five-year window, FCF Margin slumped 1103001 bps in 2022 and jumped 944666 bps in 2023, its largest moves.
- Year by year, FCF Margin stood at 395.9% in 2020, then sank by 134 bps to 133.67% in 2021, then tumbled by 7514 bps to 10177.37% in 2022, then surged by 93 bps to 730.71% in 2023, then sank by 185 bps to 2079.25% in 2024.
- Per Business Quant data, the three most recent FCF Margin figures were 2079.25% in Q1 2024, 730.71% in Q4 2023, and 50.16% in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Palvella Therapeutics | 318.78 Mn | 56.92 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -2,079.25% |
| Dec 31, 2023 | -730.71% |
| Sep 30, 2023 | -50.16% |
| Jun 30, 2023 | -67.30% |
| Mar 31, 2023 | -549.45% |
| Dec 31, 2022 | -10,177.37% |
| Sep 30, 2022 | -3,019.77% |
| Jun 30, 2022 | -7,046.52% |
| Mar 31, 2022 | -209.61% |
| Dec 31, 2021 | -133.67% |
| Sep 30, 2021 | -365.64% |
| Jun 30, 2021 | 3,983.49% |
| Mar 31, 2021 | -93.58% |
| Dec 31, 2020 | 395.90% |
| Sep 30, 2020 | -261.06% |
| Jun 30, 2020 | -99.17% |
| Mar 31, 2020 | -128.63% |
| Dec 31, 2019 | -87.72% |
| Sep 30, 2019 | -85.14% |
| Jun 30, 2019 | -218.79% |